In CRC, most patients without mutated Kirsten rat sarcoma viral oncogene homolog gene (KRAS) in their tumors respond to treatment by anti-EGFR monoclonal antibodies panitumumab and cetuximab. Here, KRAS is linked to colorectal carcinoma.